Alternatively, a benefit in survival we found in stage 3 cancer patients with a higher avidity of TF-specific Abs might be the result of a more efficient blockade of TF antigen on circulating tumor cells, thus protecting against metastases through the inhibition of the TF/galectin-3 pathway. Here, TF is linked to neoplasm.